High growth reassortant influenza A virus
View Patent ↗The present invention provides a high growth reassortant influenza A virus having at least two gene segments of seasonal or pandemic strain origin, a PB1 gene segment of A/Texas/1/77 strain origin and a PA gene segment of A/Puerto Rico/8/34 (H1N1) origin coding for a PA protein comprising at least one amino acid modification at any one of positions 10, 275, 682, according to SEQ ID No. 1. Further provided are vaccine formulations comprising the reassortant influenza A virus of the invention.
1. A reassortant influenza A virus characterized in that it comprises:
at least two gene segments of seasonal or pandemic strain origin;
a PB1 gene segment of A/Texas/1/77 strain origin;
a PA gene segment of A/Puerto Rico/8/34 (PR8) origin coding for a PA protein amino acid modifications at positions 10, 275, and 682, according to the numbering of SEQ ID NO:1; and
a NP protein that has at least one amino acid substitution at any one of positions 130, 236 and 452 according to the numbering of SEQ ID NO: 10.
2. A reassortant influenza A virus according to claim 1 , comprising a PB2 protein that comprises at least one of the amino acid modifications selected from the group consisting of I504V, V560I, and A84S according to the numbering of SEQ ID NO:6.
3. A reassortant influenza A virus characterized in that it comprises:
at least two gene segments of seasonal or pandemic strain origin;
a PB1 gene segment of A/Texas/1/77 strain origin;
a PA gene segment of A/Puerto Rico/8/34 (PR8) origin coding for a PA protein amino acid modifications at positions 10, 275 and 682, according to the numbering of SEQ ID NO: 1; and
a NP protein with at least one of the amino acid modifications selected from the group consisting of T130M, K236R, and R452K according to the numbering of SEQ ID NO: 10.
4. A reassortant influenza A virus according to claim 1 , characterized in that the polynucleotide encoding the NS1 protein comprises a modification, substitution and/or deletion of at least one nucleotide.
5. A reassortant influenza A virus according to claim 1 , characterized in that at least two gene segments are derived from an H5N1 strain.
6. A reassortant influenza A virus characterized in that it comprises:
at least two gene segments of seasonal or pandemic strain origin;
a PB1 gene segment of A/Texas/1/77 strain origin;
a PA gene segment of A/Puerto Rico/8/34 (PR8) origin coding for a PA protein comprising amino acid modifications N10S, P275L, and D682N according to the numbering of SEQ ID NO: 1;
a PB2 protein comprising amino acids modifications 1504V and/or V560I and/or A84S according to the numbering of SEQ ID NO: 6;
a NP protein with one or more amino acid modifications selected from the group consisting of T130M, K236R, and R452K according to the numbering of SEQ ID NO: 10; and
an NS1 protein comprising a modification, substitution and/or deletion of at least one nucleotide.
7. A reassortant influenza A virus according to claim 5 , wherein at least two gene segments are derived from an A/Vietnam/1203/04 strain.
8. A vaccine comprising the reassortant influenza virus of claim 6 .
9. A vaccine according to claim 8 which is formulated for intranasal delivery.
10. A reassortant influenza A virus according to claim 3 , comprising a PB2 protein that comprises at least one of the amino acid modifications selected from the group consisting of I504V, V560I, and A84S according to the numbering of SEQ ID NO:6.
11. A reassortant influenza A virus according to claim 3 , characterized in that the polynucleotide encoding the NS1 protein comprises a modification, substitution and/or deletion of at least one nucleotide.
12. A reassortant influenza A virus according to claim 3 , characterized in that at least two gene segments are derived from an H5N1 strain.
13. A reassortant influenza A virus according to claim 12 , wherein the H5N1 strain is an A/Vietnam/1203/04 strain.
14. A vaccine comprising the reassortant influenza virus of claim 3 .
15. A vaccine according to claim 14 which is formulated for intranasal delivery.
16. A vaccine comprising the reassortant influenza virus of claim 1 .
17. A vaccine according to claim 16 which is formulated for intranasal delivery.